SECTORS TODAY
Tech XLK -4.89%
Financials XLF -0.76%
Healthcare XLV +0.45%
Energy XLE +1.91%
Industrials XLI -1.60%
Cons. Disc. XLY -0.71%
Cons. Staples XLP +1.41%
Utilities XLU +0.67%
Materials XLB +0.40%
Real Estate XLRE +0.26%
Comm. Svcs XLC -1.29%

Earnings release · SYK

STRYKER REPORTS THIRD QUARTER 2026 OPERATING RESULTS

Stryker Corp. · Filed · SEC Form 8-K, Item 2.02

Stryker Corp. company page Original on SEC.gov ↗

Revenue $6.5 billion +7.7% vs a year ago
EPS $1.96 −11.7% vs a year ago
Guidance revisedoutlook statement
Automated extract. The items below were picked out of the company's press release by software and may be wrong or incomplete. Please read the original before relying on any figure. Not investment advice.

Why it matters

Revenue rose 7.7% year on year to $6.5 billion, while EPS declined 11.7% to $1.96. Higher sales with lower EPS can point to rising costs, tax or share-count effects, so the income statement in the original release is worth checking. The company revised its guidance; the original release shows which items moved and by how much.

Written automatically by Stocknote's note engine from the figures on this page and the company's previous release. Every number in this note is checked against those figures. Not investment advice.

What the company states

Revenue

$6.5 billion +7.7% vs a year ago

…Reported net sales increased 7.7% to $6.5 billion…
EPS

$1.96 −11.7% vs a year ago

…Reported net earnings per diluted share of $1.96 decreased 11.7% in the quarter.…
Guidance

Guidance revised

…We are updating our full year 2026 guidance and now expect organic net sales growth(2) in the range of 6.5% to 7.0% and adjusted net earnings per diluted share(2) to be in the range of $14.80 to $14.90.…

Read the original press release on SEC.gov ↗ Filing index ↗

Trend: last 1 reports

All releases →

Revenue growth (YoY)

EPS growth (YoY)

Oct 29, 2026 −11.7%
Disclaimer: This page is generated automatically from public SEC filings for information only. Stocknote does not edit the company's release and does not guarantee the accuracy of the extracted items. Read the full disclaimer here.

Get new research in your inbox

Forensic equity research on US stocks. No spam, unsubscribe anytime.